HEADER TRANSCRIPTION 06-OCT-08 3ET0 TITLE STRUCTURE OF PPARGAMMA WITH 3-(5-METHOXY-1H-INDOL-3-YL)-PROPIONIC ACID COMPND MOL_ID: 1; COMPND 2 MOLECULE: PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: LIGAND BINDING DOMAIN; COMPND 5 SYNONYM: PPAR-GAMMA, NUCLEAR RECEPTOR SUBFAMILY 1 GROUP C MEMBER 3; COMPND 6 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: PPARG, NR1C3; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21(DE3)RIL; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PET-28 KEYWDS PPAR, PPARG, PPARGAMMA, DRUG DISCOVERY, DIABETES, ADIPONECTIN, KEYWDS 2 METABOLIC DISEASE, FRAGMENT-BASED DRUG DISCOVERY, SCAFFOLD-BASED KEYWDS 3 DRUG DISCOVERY, ACTIVATOR, ALTERNATIVE SPLICING, DIABETES MELLITUS, KEYWDS 4 DISEASE MUTATION, DNA-BINDING, METAL-BINDING, NUCLEUS, OBESITY, KEYWDS 5 PHOSPHOPROTEIN, POLYMORPHISM, RECEPTOR, TRANSCRIPTION, TRANSCRIPTION KEYWDS 6 REGULATION, ZINC, ZINC-FINGER EXPDTA X-RAY DIFFRACTION AUTHOR K.Y.J.ZHANG,W.WANG REVDAT 4 13-NOV-24 3ET0 1 REMARK REVDAT 3 06-SEP-23 3ET0 1 HETSYN REVDAT 2 29-JUL-20 3ET0 1 COMPND REMARK SEQADV HETNAM REVDAT 2 2 1 LINK SITE REVDAT 1 17-FEB-09 3ET0 0 JRNL AUTH D.R.ARTIS,J.J.LIN,C.ZHANG,W.WANG,U.MEHRA,M.PERREAULT,D.ERBE, JRNL AUTH 2 H.I.KRUPKA,B.P.ENGLAND,J.ARNOLD,A.N.PLOTNIKOV,A.MARIMUTHU, JRNL AUTH 3 H.NGUYEN,S.WILL,M.SIGNAEVSKY,J.KRAL,J.CANTWELL, JRNL AUTH 4 C.SETTACHATGULL,D.S.YAN,D.FONG,A.OH,S.SHI,P.WOMACK,B.POWELL, JRNL AUTH 5 G.HABETS,B.L.WEST,K.Y.ZHANG,M.V.MILBURN,G.P.VLASUK, JRNL AUTH 6 K.P.HIRTH,K.NOLOP,G.BOLLAG,P.N.IBRAHIM,J.F.TOBIN JRNL TITL SCAFFOLD-BASED DISCOVERY OF INDEGLITAZAR, A PPAR PAN-ACTIVE JRNL TITL 2 ANTI-DIABETIC AGENT JRNL REF PROC.NATL.ACAD.SCI.USA V. 106 262 2009 JRNL REFN ISSN 0027-8424 JRNL PMID 19116277 JRNL DOI 10.1073/PNAS.0811325106 REMARK 2 REMARK 2 RESOLUTION. 2.40 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : ML REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.40 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 29.19 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.340 REMARK 3 COMPLETENESS FOR RANGE (%) : 96.3 REMARK 3 NUMBER OF REFLECTIONS : 25523 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.203 REMARK 3 R VALUE (WORKING SET) : 0.200 REMARK 3 FREE R VALUE : 0.255 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.160 REMARK 3 FREE R VALUE TEST SET COUNT : 1318 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 29.1901 - 4.9849 0.95 2745 147 0.1732 0.1959 REMARK 3 2 4.9849 - 3.9598 0.97 2721 160 0.1590 0.2144 REMARK 3 3 3.9598 - 3.4602 0.98 2702 160 0.1913 0.2280 REMARK 3 4 3.4602 - 3.1442 0.98 2736 152 0.2308 0.2948 REMARK 3 5 3.1442 - 2.9191 0.96 2683 145 0.2388 0.3352 REMARK 3 6 2.9191 - 2.7471 0.96 2670 145 0.2297 0.2830 REMARK 3 7 2.7471 - 2.6096 0.96 2669 136 0.2252 0.3193 REMARK 3 8 2.6096 - 2.4961 0.96 2658 143 0.2328 0.3297 REMARK 3 9 2.4961 - 2.4000 0.95 2621 130 0.2435 0.3435 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : FLAT BULK SOLVENT MODEL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : 0.33 REMARK 3 B_SOL : 70.36 REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.400 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : NULL REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : NULL NULL REMARK 3 ANGLE : NULL NULL REMARK 3 CHIRALITY : NULL NULL REMARK 3 PLANARITY : NULL NULL REMARK 3 DIHEDRAL : NULL NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 2 REMARK 3 TLS GROUP : 1 REMARK 3 SELECTION: CHAIN A REMARK 3 ORIGIN FOR THE GROUP (A): 13.3078 55.8269 17.1726 REMARK 3 T TENSOR REMARK 3 T11: 0.3289 T22: 0.4897 REMARK 3 T33: 0.3615 T12: 0.1169 REMARK 3 T13: -0.0051 T23: 0.0395 REMARK 3 L TENSOR REMARK 3 L11: 0.4799 L22: 1.4230 REMARK 3 L33: 1.0190 L12: 0.0878 REMARK 3 L13: -0.0454 L23: 0.1747 REMARK 3 S TENSOR REMARK 3 S11: -0.1834 S12: -0.1489 S13: -0.1493 REMARK 3 S21: -0.0709 S22: 0.2492 S23: -0.1859 REMARK 3 S31: -0.0617 S32: 0.2484 S33: 0.0000 REMARK 3 TLS GROUP : 2 REMARK 3 SELECTION: CHAIN B REMARK 3 ORIGIN FOR THE GROUP (A): 30.8797 33.3595 34.2035 REMARK 3 T TENSOR REMARK 3 T11: 0.4314 T22: 0.2692 REMARK 3 T33: 0.3656 T12: 0.1508 REMARK 3 T13: 0.0092 T23: 0.0495 REMARK 3 L TENSOR REMARK 3 L11: 1.8159 L22: 0.4388 REMARK 3 L33: 2.3063 L12: 0.6206 REMARK 3 L13: -0.9348 L23: 0.2586 REMARK 3 S TENSOR REMARK 3 S11: 0.0912 S12: -0.1922 S13: -0.0776 REMARK 3 S21: 0.0817 S22: -0.0018 S23: 0.1210 REMARK 3 S31: -0.2257 S32: 0.2225 S33: -0.0000 REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 3ET0 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 08-OCT-08. REMARK 100 THE DEPOSITION ID IS D_1000049729. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 05-JUN-02 REMARK 200 TEMPERATURE (KELVIN) : 180 REMARK 200 PH : 7.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ALS REMARK 200 BEAMLINE : 5.0.1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.1 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 210 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 26349 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.400 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 0.9 REMARK 200 DATA REDUNDANCY : 2.600 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : 0.04600 REMARK 200 FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.40 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.55 REMARK 200 COMPLETENESS FOR SHELL (%) : 94.2 REMARK 200 DATA REDUNDANCY IN SHELL : 2.50 REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : 0.39100 REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: CCP4 REMARK 200 STARTING MODEL: PDB ENTRY 2PRG REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 51.75 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.55 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: THE PURIFIED PPARG LIGAND BINDING REMARK 280 DOMAIN (LBD) PROTEIN WAS DILUATED TO 12 MG/ML AND 1MM OF REMARK 280 COMPOUND 1 WAS ADDED TO THE PROTEIN PRIOR TO CRYSTALLIZATION BY REMARK 280 MIXING EQUAL VOLUMES OF PROTEIN/COMPOUND SAMPLE WITH RESERVOIR REMARK 280 SOLUTION CONTAINING 0.9 M SODIUM CITRATE AND 0.1 M 4-(2- REMARK 280 HYDROXYETHYL)-1-PIPERAZINEETHANESULFONIC ACID (HEPES) AT PH 7.5, REMARK 280 VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 277K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 46.67450 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 31.22550 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 46.67450 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 31.22550 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 186 REMARK 465 GLY A 187 REMARK 465 SER A 188 REMARK 465 SER A 189 REMARK 465 HIS A 190 REMARK 465 HIS A 191 REMARK 465 HIS A 192 REMARK 465 HIS A 193 REMARK 465 HIS A 194 REMARK 465 HIS A 195 REMARK 465 SER A 196 REMARK 465 SER A 197 REMARK 465 GLY A 198 REMARK 465 LEU A 199 REMARK 465 VAL A 200 REMARK 465 PRO A 201 REMARK 465 ARG A 202 REMARK 465 GLY A 203 REMARK 465 SER A 204 REMARK 465 HIS A 205 REMARK 465 LYS A 263 REMARK 465 PHE A 264 REMARK 465 LYS A 265 REMARK 465 HIS A 266 REMARK 465 ILE A 267 REMARK 465 THR A 268 REMARK 465 PRO A 269 REMARK 465 LEU A 270 REMARK 465 GLN A 271 REMARK 465 GLU A 272 REMARK 465 GLN A 273 REMARK 465 SER A 274 REMARK 465 MET B 186 REMARK 465 GLY B 187 REMARK 465 SER B 188 REMARK 465 SER B 189 REMARK 465 HIS B 190 REMARK 465 HIS B 191 REMARK 465 HIS B 192 REMARK 465 HIS B 193 REMARK 465 HIS B 194 REMARK 465 HIS B 195 REMARK 465 SER B 196 REMARK 465 SER B 197 REMARK 465 GLY B 198 REMARK 465 LEU B 199 REMARK 465 VAL B 200 REMARK 465 PRO B 201 REMARK 465 ARG B 202 REMARK 465 GLY B 203 REMARK 465 SER B 204 REMARK 465 HIS B 205 REMARK 465 LYS B 263 REMARK 465 PHE B 264 REMARK 465 LYS B 265 REMARK 465 HIS B 266 REMARK 465 ILE B 267 REMARK 465 THR B 268 REMARK 465 PRO B 269 REMARK 465 LEU B 270 REMARK 465 GLN B 271 REMARK 465 GLU B 272 REMARK 465 GLN B 273 REMARK 465 SER B 274 REMARK 465 TYR B 477 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LYS A 240 27.70 -70.72 REMARK 500 ASP A 243 79.80 -51.96 REMARK 500 LYS A 244 117.88 -31.95 REMARK 500 SER A 245 163.33 -47.43 REMARK 500 GLU A 259 25.71 -69.32 REMARK 500 LYS A 261 27.35 -176.60 REMARK 500 ASP A 310 134.39 -39.09 REMARK 500 SER A 342 57.69 36.76 REMARK 500 LYS A 358 -92.50 -13.82 REMARK 500 GLU A 460 74.78 -119.83 REMARK 500 LYS B 240 58.61 -69.55 REMARK 500 GLU B 259 38.88 -77.58 REMARK 500 LYS B 261 9.61 174.59 REMARK 500 LYS B 358 -75.53 -6.36 REMARK 500 VAL B 455 39.23 -73.51 REMARK 500 ILE B 456 7.13 -60.58 REMARK 500 LYS B 457 41.49 -80.18 REMARK 500 THR B 459 -177.19 82.39 REMARK 500 GLU B 460 48.07 71.27 REMARK 500 THR B 461 -82.83 63.51 REMARK 500 SER B 464 31.78 92.19 REMARK 500 ASP B 475 -101.89 -128.69 REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 3ET1 RELATED DB: PDB REMARK 900 STRUCTURE OF PPARALPHA WITH 3-[5-METHOXY-1-(4-METHOXY- REMARK 900 BENZENESULFONYL)-1H-INDOL-3-YL]-PROPIONIC ACID REMARK 900 RELATED ID: 3ET2 RELATED DB: PDB REMARK 900 STRUCTURE OF PPARDELTA WITH 3-[5-METHOXY-1-(4-METHOXY- REMARK 900 BENZENESULFONYL)-1H-INDOL-3-YL]-PROPIONIC ACID REMARK 900 RELATED ID: 3ET3 RELATED DB: PDB REMARK 900 STRUCTURE OF PPARGAMMA WITH 3-[5-METHOXY-1-(4-METHOXY- REMARK 900 BENZENESULFONYL)-1H-INDOL-3-YL]-PROPIONIC ACID DBREF 3ET0 A 207 477 UNP P37231 PPARG_HUMAN 235 505 DBREF 3ET0 B 207 477 UNP P37231 PPARG_HUMAN 235 505 SEQADV 3ET0 MET A 186 UNP P37231 EXPRESSION TAG SEQADV 3ET0 GLY A 187 UNP P37231 EXPRESSION TAG SEQADV 3ET0 SER A 188 UNP P37231 EXPRESSION TAG SEQADV 3ET0 SER A 189 UNP P37231 EXPRESSION TAG SEQADV 3ET0 HIS A 190 UNP P37231 EXPRESSION TAG SEQADV 3ET0 HIS A 191 UNP P37231 EXPRESSION TAG SEQADV 3ET0 HIS A 192 UNP P37231 EXPRESSION TAG SEQADV 3ET0 HIS A 193 UNP P37231 EXPRESSION TAG SEQADV 3ET0 HIS A 194 UNP P37231 EXPRESSION TAG SEQADV 3ET0 HIS A 195 UNP P37231 EXPRESSION TAG SEQADV 3ET0 SER A 196 UNP P37231 EXPRESSION TAG SEQADV 3ET0 SER A 197 UNP P37231 EXPRESSION TAG SEQADV 3ET0 GLY A 198 UNP P37231 EXPRESSION TAG SEQADV 3ET0 LEU A 199 UNP P37231 EXPRESSION TAG SEQADV 3ET0 VAL A 200 UNP P37231 EXPRESSION TAG SEQADV 3ET0 PRO A 201 UNP P37231 EXPRESSION TAG SEQADV 3ET0 ARG A 202 UNP P37231 EXPRESSION TAG SEQADV 3ET0 GLY A 203 UNP P37231 EXPRESSION TAG SEQADV 3ET0 SER A 204 UNP P37231 EXPRESSION TAG SEQADV 3ET0 HIS A 205 UNP P37231 EXPRESSION TAG SEQADV 3ET0 MET A 206 UNP P37231 EXPRESSION TAG SEQADV 3ET0 MET B 186 UNP P37231 EXPRESSION TAG SEQADV 3ET0 GLY B 187 UNP P37231 EXPRESSION TAG SEQADV 3ET0 SER B 188 UNP P37231 EXPRESSION TAG SEQADV 3ET0 SER B 189 UNP P37231 EXPRESSION TAG SEQADV 3ET0 HIS B 190 UNP P37231 EXPRESSION TAG SEQADV 3ET0 HIS B 191 UNP P37231 EXPRESSION TAG SEQADV 3ET0 HIS B 192 UNP P37231 EXPRESSION TAG SEQADV 3ET0 HIS B 193 UNP P37231 EXPRESSION TAG SEQADV 3ET0 HIS B 194 UNP P37231 EXPRESSION TAG SEQADV 3ET0 HIS B 195 UNP P37231 EXPRESSION TAG SEQADV 3ET0 SER B 196 UNP P37231 EXPRESSION TAG SEQADV 3ET0 SER B 197 UNP P37231 EXPRESSION TAG SEQADV 3ET0 GLY B 198 UNP P37231 EXPRESSION TAG SEQADV 3ET0 LEU B 199 UNP P37231 EXPRESSION TAG SEQADV 3ET0 VAL B 200 UNP P37231 EXPRESSION TAG SEQADV 3ET0 PRO B 201 UNP P37231 EXPRESSION TAG SEQADV 3ET0 ARG B 202 UNP P37231 EXPRESSION TAG SEQADV 3ET0 GLY B 203 UNP P37231 EXPRESSION TAG SEQADV 3ET0 SER B 204 UNP P37231 EXPRESSION TAG SEQADV 3ET0 HIS B 205 UNP P37231 EXPRESSION TAG SEQADV 3ET0 MET B 206 UNP P37231 EXPRESSION TAG SEQRES 1 A 292 MET GLY SER SER HIS HIS HIS HIS HIS HIS SER SER GLY SEQRES 2 A 292 LEU VAL PRO ARG GLY SER HIS MET GLU SER ALA ASP LEU SEQRES 3 A 292 ARG ALA LEU ALA LYS HIS LEU TYR ASP SER TYR ILE LYS SEQRES 4 A 292 SER PHE PRO LEU THR LYS ALA LYS ALA ARG ALA ILE LEU SEQRES 5 A 292 THR GLY LYS THR THR ASP LYS SER PRO PHE VAL ILE TYR SEQRES 6 A 292 ASP MET ASN SER LEU MET MET GLY GLU ASP LYS ILE LYS SEQRES 7 A 292 PHE LYS HIS ILE THR PRO LEU GLN GLU GLN SER LYS GLU SEQRES 8 A 292 VAL ALA ILE ARG ILE PHE GLN GLY CME GLN PHE ARG SER SEQRES 9 A 292 VAL GLU ALA VAL GLN GLU ILE THR GLU TYR ALA LYS SER SEQRES 10 A 292 ILE PRO GLY PHE VAL ASN LEU ASP LEU ASN ASP GLN VAL SEQRES 11 A 292 THR LEU LEU LYS TYR GLY VAL HIS GLU ILE ILE TYR THR SEQRES 12 A 292 MET LEU ALA SER LEU MET ASN LYS ASP GLY VAL LEU ILE SEQRES 13 A 292 SER GLU GLY GLN GLY PHE MET THR ARG GLU PHE LEU LYS SEQRES 14 A 292 SER LEU ARG LYS PRO PHE GLY ASP PHE MET GLU PRO LYS SEQRES 15 A 292 PHE GLU PHE ALA VAL LYS PHE ASN ALA LEU GLU LEU ASP SEQRES 16 A 292 ASP SER ASP LEU ALA ILE PHE ILE ALA VAL ILE ILE LEU SEQRES 17 A 292 SER GLY ASP ARG PRO GLY LEU LEU ASN VAL LYS PRO ILE SEQRES 18 A 292 GLU ASP ILE GLN ASP ASN LEU LEU GLN ALA LEU GLU LEU SEQRES 19 A 292 GLN LEU LYS LEU ASN HIS PRO GLU SER SER GLN LEU PHE SEQRES 20 A 292 ALA LYS LEU LEU GLN LYS MET THR ASP LEU ARG GLN ILE SEQRES 21 A 292 VAL THR GLU HIS VAL GLN LEU LEU GLN VAL ILE LYS LYS SEQRES 22 A 292 THR GLU THR ASP MET SER LEU HIS PRO LEU LEU GLN GLU SEQRES 23 A 292 ILE TYR LYS ASP LEU TYR SEQRES 1 B 292 MET GLY SER SER HIS HIS HIS HIS HIS HIS SER SER GLY SEQRES 2 B 292 LEU VAL PRO ARG GLY SER HIS MET GLU SER ALA ASP LEU SEQRES 3 B 292 ARG ALA LEU ALA LYS HIS LEU TYR ASP SER TYR ILE LYS SEQRES 4 B 292 SER PHE PRO LEU THR LYS ALA LYS ALA ARG ALA ILE LEU SEQRES 5 B 292 THR GLY LYS THR THR ASP LYS SER PRO PHE VAL ILE TYR SEQRES 6 B 292 ASP MET ASN SER LEU MET MET GLY GLU ASP LYS ILE LYS SEQRES 7 B 292 PHE LYS HIS ILE THR PRO LEU GLN GLU GLN SER LYS GLU SEQRES 8 B 292 VAL ALA ILE ARG ILE PHE GLN GLY CME GLN PHE ARG SER SEQRES 9 B 292 VAL GLU ALA VAL GLN GLU ILE THR GLU TYR ALA LYS SER SEQRES 10 B 292 ILE PRO GLY PHE VAL ASN LEU ASP LEU ASN ASP GLN VAL SEQRES 11 B 292 THR LEU LEU LYS TYR GLY VAL HIS GLU ILE ILE TYR THR SEQRES 12 B 292 MET LEU ALA SER LEU MET ASN LYS ASP GLY VAL LEU ILE SEQRES 13 B 292 SER GLU GLY GLN GLY PHE MET THR ARG GLU PHE LEU LYS SEQRES 14 B 292 SER LEU ARG LYS PRO PHE GLY ASP PHE MET GLU PRO LYS SEQRES 15 B 292 PHE GLU PHE ALA VAL LYS PHE ASN ALA LEU GLU LEU ASP SEQRES 16 B 292 ASP SER ASP LEU ALA ILE PHE ILE ALA VAL ILE ILE LEU SEQRES 17 B 292 SER GLY ASP ARG PRO GLY LEU LEU ASN VAL LYS PRO ILE SEQRES 18 B 292 GLU ASP ILE GLN ASP ASN LEU LEU GLN ALA LEU GLU LEU SEQRES 19 B 292 GLN LEU LYS LEU ASN HIS PRO GLU SER SER GLN LEU PHE SEQRES 20 B 292 ALA LYS LEU LEU GLN LYS MET THR ASP LEU ARG GLN ILE SEQRES 21 B 292 VAL THR GLU HIS VAL GLN LEU LEU GLN VAL ILE LYS LYS SEQRES 22 B 292 THR GLU THR ASP MET SER LEU HIS PRO LEU LEU GLN GLU SEQRES 23 B 292 ILE TYR LYS ASP LEU TYR MODRES 3ET0 CME A 285 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE MODRES 3ET0 CME B 285 CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE HET CME A 285 10 HET CME B 285 10 HET ET0 A 1 16 HET GLC B 2 12 HETNAM CME S,S-(2-HYDROXYETHYL)THIOCYSTEINE HETNAM ET0 3-(5-METHOXY-1H-INDOL-3-YL)PROPANOIC ACID HETNAM GLC ALPHA-D-GLUCOPYRANOSE HETSYN GLC ALPHA-D-GLUCOSE; D-GLUCOSE; GLUCOSE FORMUL 1 CME 2(C5 H11 N O3 S2) FORMUL 3 ET0 C12 H13 N O3 FORMUL 4 GLC C6 H12 O6 FORMUL 5 HOH *98(H2 O) HELIX 1 1 GLU A 207 PHE A 226 1 20 HELIX 2 2 THR A 229 THR A 238 1 10 HELIX 3 3 ASP A 251 GLU A 259 1 9 HELIX 4 4 GLU A 276 ILE A 303 1 28 HELIX 5 5 GLY A 305 LEU A 309 5 5 HELIX 6 6 ASP A 310 ALA A 331 1 22 HELIX 7 7 SER A 342 GLY A 344 5 3 HELIX 8 8 ARG A 350 SER A 355 1 6 HELIX 9 9 ARG A 357 PHE A 363 5 7 HELIX 10 10 MET A 364 ALA A 376 1 13 HELIX 11 11 ASP A 380 LEU A 393 1 14 HELIX 12 12 ASN A 402 HIS A 425 1 24 HELIX 13 13 GLN A 430 GLU A 460 1 31 HELIX 14 14 HIS A 466 LYS A 474 1 9 HELIX 15 15 GLU B 207 PHE B 226 1 20 HELIX 16 16 THR B 229 GLY B 239 1 11 HELIX 17 17 ASP B 251 GLU B 259 1 9 HELIX 18 18 GLU B 276 ILE B 303 1 28 HELIX 19 19 GLY B 305 LEU B 309 5 5 HELIX 20 20 ASP B 310 SER B 332 1 23 HELIX 21 21 SER B 342 GLY B 344 5 3 HELIX 22 22 ARG B 350 SER B 355 1 6 HELIX 23 23 PRO B 359 PHE B 363 5 5 HELIX 24 24 MET B 364 ALA B 376 1 13 HELIX 25 25 ASP B 380 LEU B 393 1 14 HELIX 26 26 ASN B 402 HIS B 425 1 24 HELIX 27 27 GLN B 430 GLN B 454 1 25 HELIX 28 28 THR B 459 SER B 464 1 6 HELIX 29 29 HIS B 466 TYR B 473 1 8 SHEET 1 A 4 PHE A 247 ILE A 249 0 SHEET 2 A 4 GLY A 346 THR A 349 1 O PHE A 347 N ILE A 249 SHEET 3 A 4 GLY A 338 ILE A 341 -1 N VAL A 339 O MET A 348 SHEET 4 A 4 MET A 334 ASN A 335 -1 N ASN A 335 O GLY A 338 SHEET 1 B 4 PHE B 247 ILE B 249 0 SHEET 2 B 4 GLY B 346 THR B 349 1 O PHE B 347 N ILE B 249 SHEET 3 B 4 GLY B 338 ILE B 341 -1 N VAL B 339 O MET B 348 SHEET 4 B 4 MET B 334 ASN B 335 -1 N ASN B 335 O GLY B 338 LINK C GLY A 284 N CME A 285 1555 1555 1.33 LINK C CME A 285 N GLN A 286 1555 1555 1.33 LINK C GLY B 284 N CME B 285 1555 1555 1.33 LINK C CME B 285 N GLN B 286 1555 1555 1.33 CRYST1 93.349 62.451 119.242 90.00 101.73 90.00 C 1 2 1 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.010712 0.000000 0.002224 0.00000 SCALE2 0.000000 0.016013 0.000000 0.00000 SCALE3 0.000000 0.000000 0.008565 0.00000